FDA licensed the first-ever vaccine for RSV last week. Vaccines for RSV have been researched for at least 20 years. The is called Arexvy (GSK). The vaccine is licensed for adults ages 60 and older. A similar vaccine from Pfizer is expected to be approved in June (same demographic).
CDC still needs to recommend the vaccine before it will be available. The next Advisory Committee on Immunization Practices meeting is on June 21/22.
A vaccine to protect infants is expected to gain FDA approval later this year. That one is developed by Pfizer. It’s expected to be licensed to give to pregnant women. Infants would be protected by passive immunity as antibodies pass through the placenta.
